The first medical invention index is out! AstraZeneca tops the list

"Innovation" is the engine to bring more new and good drugs to patients, "innovation" is also the blood to maintain the life of biomedical companies But how to define "innovation"? Does high R & D investment mean that a company focuses on innovation? Can the number of new drugs introduced define the success of innovation? Or is the number of innovators in the drug R & D pipeline the "gold standard" for predicting the company's future innovation performance? Today, idea Pharma released its first pharmaceutical invention index, which measures pharmaceutical companies' innovation from a new perspective Idea Pharma is a consulting firm focused on helping pharmaceutical companies push their products into the market from the development stage Its customers include BMS, Genentech, Johnson & Johnson, Novartis and other famous pharmaceutical companies The company's six-year-old pharmaceutical innovation index aims to answer the question: "if you give the same molecule in the early clinical stage to two different companies, who can more successfully turn it into an influential new drug?" Earlier this year, the company launched the 2019 pharmaceutical innovation index, with Gilead Sciences, abbvie and Eli Lilly in the top three Today's pharmaceutical innovation index is different from the pharmaceutical innovation index It evaluates the ability of pharmaceutical companies to discover innovation in research therapy and the "innovation" of research therapy in the research pipeline According to a press release released by idea Pharma, the index is calculated by reference to four key criteria: The proportion of the number of research therapies in the company's R & D pipeline to the number of drugs already on the market The number of innovative drugs in clinical trials The proportion of "innovation" regulatory qualification in research therapy Evaluation of R & D investment of the company "There is an important difference between invention and innovation," said Mike rea, CEO of idea pharma The success of pharmaceutical companies requires not only the discovery and development of meaningful candidate drugs (Inventions), but also their successful marketing to bring patients (innovation) " Here are the top 11 pharmaceutical companies in this year's Pharmaceutical Invention index (vertex and Alberto are tied for fifth place on this year's list): AstraZeneca is at the top of the Pharmaceutical Invention index this year, ranking at the top of all four indicators, and is committed to continuous improvement of its R & D system In the third quarter of this year's financial report conference call, AstraZeneca also showed a number of potential research and development pipeline in research and development therapy Under the leadership of Pascal soriot, the company's chief executive officer, AstraZeneca's new drug research and development takes on a new look "I'm glad to see that companies of the size of AstraZeneca are able to make significant progress in new drug research and development in a relatively short period of time," Mr Mike rea said Source: reference [5] How to define innovation is a matter of different opinions Today, idea Pharma's Pharmaceutical Invention index only evaluates the breadth and innovation of R & D pipeline of pharmaceutical enterprises from one perspective Mr Mike rea once pointed out that of the 59 new drugs approved in 2018, 39 were from small and medium-sized biomedical companies not on the pharmaceutical innovation index This means that a large part of innovation in the field of medicine does not come from the large pharmaceutical companies on the list However, no matter what kind of definition innovation is given, no matter where innovation comes from, support more innovation, so as to bring more new drugs and good drugs, and achieve the ultimate goal of benefiting patients reference material: [1] AstraZeneca Tops the First Pharmaceutical Invention Index Retrieved November 4, 2019, from https:// [2] Pharmaceutical Innovation Index 2019 Retrieved November 4, 2019, from http://ideapharma.com/resources/pii-white-paper-2019.pdf [3] The 2019 Pharmaceutical Innovation Index Retrieved November 4, 2019, from https:// [4] Company profile: IDEA Pharma Retrieved November 4, 2019, from https://deep-dive.pharmaphorum.com/magazine/pharma-research-rare-diseases/idea-pharma-strategy/ [5] Year-to-date and Q3 2019 results Retrieved November 4, 2019, from https:// [6] AstraZeneca wins kudos for pipeline turnaround in a new ranking of the top 10 R&D players in the biopharma world Retrieved November 4, 2019, from https://endpts.com/astrazeneca-wins-kudos-for-pipeline-turnaround-in-a-new-ranking-of-the-top-10-rd-players-in-the-biopharma-world/ A kind of